Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Describe the epidemiological characteristics of the study population
研究概览
简要总结
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 0 Years 至 30 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria.
- •Signature of the consent form for participation in the FIMBANK project.
- •Agreement to participate in the VYP study.
- •Patient of legal age at the time of inclusion in VYP.
- •Patient affiliated to a social security scheme
排除标准
- •Refusal to participate by patients of full age
- •Patient under legal protection (guardianship, curatorship, etc.)
结局指标
主要结局
Describe the epidemiological characteristics of the study population
时间窗: at enrollment
Description of MPN subtypes according to age
Describe the mutational landscape of these MPNs
时间窗: at enrollment
Rate of mutations JAK2/CALR/MPL
次要结局
- Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1(At 10 years)
- Describe the classical MPN outcomes-2(At 10 years)
- Describe the classical MPN outcomes-3(At 10 years)
